AR074219A1 - Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan - Google Patents
Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalanInfo
- Publication number
- AR074219A1 AR074219A1 ARP090104545A ARP090104545A AR074219A1 AR 074219 A1 AR074219 A1 AR 074219A1 AR P090104545 A ARP090104545 A AR P090104545A AR P090104545 A ARP090104545 A AR P090104545A AR 074219 A1 AR074219 A1 AR 074219A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- melfalan
- antitumoral
- specifically recognize
- cell
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 title abstract 2
- 229960001924 melphalan Drugs 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291116A EP2191840A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074219A1 true AR074219A1 (es) | 2010-12-29 |
Family
ID=40578382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104545A AR074219A1 (es) | 2008-11-28 | 2009-11-25 | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan |
Country Status (32)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0816777B2 (ja) | 1988-10-13 | 1996-02-21 | 富士写真フイルム株式会社 | 画像形成方法 |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| WO2011130624A2 (en) * | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT2621531T (pt) | 2010-09-27 | 2017-03-13 | Morphosys Ag | Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins |
| EP2622064B1 (en) | 2010-10-01 | 2019-05-29 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| HRP20171964T1 (hr) * | 2012-09-25 | 2018-02-23 | Morphosys Ag | Kombinacije i njihova upotreba |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EA035098B1 (ru) * | 2014-07-31 | 2020-04-27 | Санофи | Способ лечения рецидивирующей и/или рефрактерной множественной миеломы |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による併用療法 |
| TWI721959B (zh) | 2014-12-04 | 2021-03-21 | 美商健生生物科技公司 | 治療急性骨髓性白血病之抗ｃｄ３８抗體 |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| NZ777133A (en) | 2015-06-22 | 2025-05-02 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| SMT202100192T1 (it) | 2015-11-03 | 2021-05-07 | Janssen Biotech Inc | Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi. |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CN109689690B (zh) | 2016-07-15 | 2023-10-03 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| WO2019130228A1 (en) * | 2018-01-01 | 2019-07-04 | Orbicular Pharmaceutical Technologies Pvt. Ltd., | Stable liquid compositions of melphalan |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| KR20210068485A (ko) | 2018-09-28 | 2021-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍 |
| US20220144965A1 (en) | 2019-03-15 | 2022-05-12 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| BR112022010905A2 (pt) | 2019-12-05 | 2022-09-06 | Sanofi Aventis Us Llc | Formulações de anticorpos anti-cd38 para administração subcutânea |
| US20240109977A1 (en) | 2021-01-14 | 2024-04-04 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999062526A2 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| NZ548990A (en) | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| NZ561883A (en) * | 2005-03-23 | 2010-11-26 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| HUE044136T2 (hu) | 2006-09-26 | 2019-09-30 | Genmab As | Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére |
| US20080092384A1 (en) * | 2006-10-16 | 2008-04-24 | Schaake Mark D | Installation of Middle Bearing for a Crankshaft |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
-
2008
- 2008-11-28 EP EP08291116A patent/EP2191840A1/en not_active Ceased
-
2009
- 2009-11-25 AR ARP090104545A patent/AR074219A1/es not_active Application Discontinuation
- 2009-11-25 UY UY0001032263A patent/UY32263A/es not_active Application Discontinuation
- 2009-11-25 PA PA20098850101A patent/PA8850101A1/es unknown
- 2009-11-25 TW TW098140158A patent/TWI454260B/zh active
- 2009-11-27 PE PE2011001107A patent/PE20120340A1/es active IP Right Grant
- 2009-11-27 ME MEP-2011-93A patent/ME01136B/me unknown
- 2009-11-27 KR KR1020117014746A patent/KR101733252B1/ko active Active
- 2009-11-27 BR BRPI0921864-5A patent/BRPI0921864B1/pt active IP Right Grant
- 2009-11-27 US US13/130,862 patent/US9259406B2/en active Active
- 2009-11-27 AU AU2009321249A patent/AU2009321249B2/en active Active
- 2009-11-27 NZ NZ593027A patent/NZ593027A/xx unknown
- 2009-11-27 CN CN200980148094.4A patent/CN102264385B/zh active Active
- 2009-11-27 EA EA201100864A patent/EA026867B1/ru not_active IP Right Cessation
- 2009-11-27 WO PCT/IB2009/055389 patent/WO2010061357A1/en not_active Ceased
- 2009-11-27 CA CA2744990A patent/CA2744990C/en not_active Expired - Fee Related
- 2009-11-27 MY MYPI2011002367A patent/MY164577A/en unknown
- 2009-11-27 EP EP09775302A patent/EP2370094A1/en not_active Withdrawn
- 2009-11-27 MX MX2011005670A patent/MX342625B/es active IP Right Grant
- 2009-11-27 SG SG2011037967A patent/SG171820A1/en unknown
- 2009-11-27 UA UAA201108006A patent/UA107069C2/uk unknown
- 2009-11-27 JP JP2011538092A patent/JP2012510461A/ja not_active Withdrawn
-
2011
- 2011-05-11 TN TN2011000232A patent/TN2011000232A1/fr unknown
- 2011-05-19 EC EC2011011062A patent/ECSP11011062A/es unknown
- 2011-05-24 IL IL213116A patent/IL213116B/en active IP Right Grant
- 2011-05-26 CR CR20110280A patent/CR20110280A/es unknown
- 2011-05-27 NI NI201100105A patent/NI201100105A/es unknown
- 2011-05-27 ZA ZA2011/03925A patent/ZA201103925B/en unknown
- 2011-05-27 CO CO11065644A patent/CO6440557A2/es unknown
- 2011-05-27 CL CL2011001254A patent/CL2011001254A1/es unknown
- 2011-05-27 HN HN2011001417A patent/HN2011001417A/es unknown
- 2011-05-27 SV SV2011003924A patent/SV2011003924A/es unknown
- 2011-06-13 MA MA33937A patent/MA32896B1/fr unknown
-
2015
- 2015-05-27 JP JP2015107404A patent/JP6148696B2/ja active Active
-
2017
- 2017-03-01 JP JP2017037860A patent/JP2017141233A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR074221A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida | |
| AR084196A1 (es) | Composiciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 | |
| AR074220A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso | |
| ES2606173T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención del cáncer | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| JP2012510461A5 (enExample) | ||
| CL2012002012A1 (es) | Anticuerpo anti-cd38 o fragmento de este, capaz de destruir una célula cd38+ por apoptosis, citotoxicidad celular adcc y citotoxicidad cdc; anticuerpo humanizado; polinucleótido, vector y célula huésped que lo codifican; conjugado del anticuerpo con un compuesto citotóxico; composición farmacéutica con dichos anticuerpos; uso de los anticuerpos para tratar cáncer o enfermedad autoinmune; método para diagnosticar cáncer. | |
| AR071733A1 (es) | Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| CY1122366T1 (el) | Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. | |
| EA201290370A1 (ru) | Антитела против flt3 и способы их применения | |
| PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
| CO6190538A2 (es) | Agente para prevenir/tratar el cancer | |
| PE20141546A1 (es) | Anticuerpos anti-cd134(ox40) y sus usos de los mismos | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| PE20141045A1 (es) | Proteinas de union a bcma (cd269/tnfrsf17) | |
| MX337417B (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores. | |
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |